A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/435 (2006.01) A61K 31/438 (2006.01) A61K 31/444 (2006.01) A61K 31/497 (2006.01) A61K 31/501 (2006.01) A61K 31/506 (2006.01) A61P 3/04 (2006.01) A61P 25/30 (2006.01) A61P 25/34 (2006.01)
Patent
CA 2575461
Compounds, compositions and methods for treating drug addiction, nicotine addiction, and/or obesity are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteraryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds are effective at inhibiting dopamine production and/or secretion, and accordingly are effective at inhibiting the physiological "reward" process that is associated with ingestion of nicotine and/or illicit drugs. The compounds and compositions can be administered in effective amounts to inhibit dopamine release, wihout resulting in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).
L'invention concerne des composés, des compositions et des méthodes de traitement de la toxicomanie, de la dépendance à la nicotine, et/ou de l'obésité. Les composés sont des composés diazaspirocycliques N-aryle, des analogues pontés des composés diazaspirocycliques N-hétéroaryle, ou des promédicaments ou des métabolites desdits composés. Le groupe aryle peut être un noyau hétérocyclique (hétéroaryle) à cinq ou six éléments. Lesdits composés inhibent efficacement la production et/ou la sécrétion de dopamine, et inhibent ainsi efficacement le processus de "récompense" physiologique associé à l'ingestion de la nicotine et/ou de drogues illicites. Les composés et compositions de l'invention peuvent être administrés en quantités efficaces pour inhiber la libération de la dopamine, sans générer d'effets secondaires nuisibles significatifs (par exemple, des effets secondaires tels que des augmentations significatives de la pression sanguine et de la fréquence cardiaque, des effets négatifs significatifs sur le tractus gastro-intestinal, et des effets significatifs sur les muscles squelettiques).
Bhatti Balwinder Singh
Gatto Gregory J.
Klucik Jozef
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Targacept Inc.
LandOfFree
The use of n-aryl diazaspiracyclic compounds in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with The use of n-aryl diazaspiracyclic compounds in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and The use of n-aryl diazaspiracyclic compounds in the... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2010009